Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Lucentis Stories

2013-12-10 16:24:54

INCLINE VILLAGE, Nev., Dec. 10, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2013, of approximately $109 million, as compared with actual revenue of $86 million for the fourth quarter of 2012, an approximate 27 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in revenues is driven by increased third quarter 2013 sales for Avastin(®),...

2013-09-09 08:26:48

INCLINE VILLAGE, Nev., Sept. 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in revenues is driven by increased second quarter 2013 sales for Avastin(®),...

2013-08-15 08:26:16

Eylea's Convenient Dosing Frequency Likely Drives Product Initiation, Although High Satisfaction Among Prescribers Likely Motivates Continued Use, According to a New Report from BioTrends Research Group EXTON, Penn., Aug. 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed retinal specialists/general ophthalmologists now treat 26 percent of their intravitreal...

2013-07-19 15:30:13

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose. The results of a two-year trial, led by Queen's scientist Professor Usha Chakravarthy, and published in The Lancet today (Friday 19 July), show that two drug treatments Lucentis and Avastin are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD). Wet AMD is...

Promising Results From Pilot Study For AMD
2013-06-18 13:40:01

University of Iowa There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, “wet” stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two...

2013-05-29 08:28:06

Lucentis's Prescriber Base and Patient Share Have Grown But Cost-Related Obstacles Remain, According to a New Report from BioTrends Research Group EXTON, Pa., May 29, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, despite the approval of Genentech's Lucentis 0.3 mg in August 2012 as the first intravitreal therapy (IVT) for the treatment of diabetic macular edema (DME),...

2013-03-11 08:26:59

INCLINE VILLAGE, Nev., March 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) The forecasted growth in royalty revenues is driven by increased fourth quarter 2012 sales for all licensed...

2012-12-27 08:25:07

NEW YORK, Dec. 27, 2012 /PRNewswire/ -- Ohr Pharmaceutical Inc., a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets, announced today that it has published a letter to shareholders, available on the Company's website, from its Chief Executive officer, Dr. Irach B. Taraporewala, Ph.D. The letter states: Dear Shareholder, I would like to take this opportunity to share the progress we have made in 2012 and...

2012-09-06 02:30:59

INCLINE VILLAGE, Nev., Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the third quarter ending September 30, 2012, of approximately $85 million, as compared with actual royalty revenue of $83 million for the third quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased second quarter 2012 sales of...

2012-08-20 23:00:57

On August 13th, Atlanta LASIK surgeon Dr. Ashraf released findings about the drug Lucentis, approved by the FDA and used to treat eye conditions like Diabetic Macular Edema. Atlanta, GA (PRWEB) August 20, 2012 On August 13th, Dr. Ashraf of the Atlanta Vision Institute released information about a study that was performed using Lucentis, a drug approved by the FDA that treats Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). AMD is an eye condition that is common among...